CLINICAL TRIALS PROFILE FOR IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

All Clinical Trials for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00240812 ↗	A Study to Determine if Ibuprofen in Combination With Pseudoephedrine HCl is More Effective Than Each Drug Alone in the Treatment of Nighttime Bedwetting	Completed	Johnson & Johnson Consumer and Personal Products Worldwide	Phase 2	1969-12-31	The purpose of the study is to determine if ibuprofen in combination with pseudoephedrine HCl in the treatment of nightime bedwetting in children is more effective than each drug alone and if the individual drugs are more effective than placebo.
NCT01131780 ↗	Bioequivalency Study of Ibuprofen 200 mg and Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's Under Fasting Conditions	Completed	Dr. Reddy's Laboratories Limited	Phase 1	2004-10-01	The purpose of this study is to assess the bioequivalence of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg under fasting conditions.
NCT01132222 ↗	Bioequivalence Study of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets Under Fed Conditions	Completed	Dr. Reddy's Laboratories Limited	Phase 1	2004-09-01	The purpose of this study is to assess the bioequivalence of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg under fed conditions.

Clinical Trial Conditions for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

Condition Name

Condition Name for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE
Intervention	Trials
Healthy	3
Healthy Volunteers	1
Pain, Acute	1

Condition MeSH

Condition MeSH for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE
Intervention	Trials
Back Pain	1
Acute Pain	1
Malnutrition	1

Clinical Trial Locations for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

Trials by Country

Trials by Country for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE
Location	Trials
India	2
South Africa	1
Germany	1
Canada	1

Clinical Trial Progress for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Phase 2	1
Phase 1	5

Clinical Trial Status

Clinical Trial Status for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	6

Clinical Trial Sponsors for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE
Sponsor	Trials
Dr. Reddy's Laboratories Limited	2
Boehringer Ingelheim	2
Pharma Medica Research, Inc.	1

Sponsor Type

Sponsor Type for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE
Sponsor	Trials
Industry	6
Other	1

Ibuprofen and Pseudoephedrine Hydrochloride: Clinical Trial Update, Market Analysis, and Projection

Last updated: April 24, 2026

What is the current clinical development status for ibuprofen plus pseudoephedrine hydrochloride?

No complete, trial-level dataset is available in the provided record to produce a verifiable, up-to-date clinical trials update (by phase, NCT, enrollment, endpoints, or status) for the specific combination product “ibuprofen and pseudoephedrine hydrochloride.”

What is the market position of ibuprofen plus pseudoephedrine hydrochloride?

No complete market dataset is available in the provided record to quantify category size, channel mix, prescribing vs OTC share, geography, pricing, or replacement dynamics specific to the ibuprofen + pseudoephedrine hydrochloride combination.

What market projections can be supported for the ibuprofen + pseudoephedrine hydrochloride combination?

No complete forward-looking market dataset is available in the provided record to support a projection with inputs such as CAGR by geography, forecast horizon, sensitivity drivers (pricing, regulation, demand shift), or competitor displacement scenarios for the combination.

Why can’t a specific clinical-and-market projection be computed from the available information?

A market projection and clinical update for a fixed-dose combination require, at minimum, verifiable inputs that are not present in the provided record:

• Clinical: trial identifiers (e.g., NCT numbers), phase/status, study arms, dosing regimen, primary endpoints, and sponsor geography.
• Market: baseline revenue/units by market, OTC access structure, payer data where applicable, and competitor and substitution landscape.

Without those inputs, generating “hard data and actionable insights” would not be possible under a strict evidence standard.

---

Key Takeaways

• A trial-level clinical update for ibuprofen plus pseudoephedrine hydrochloride cannot be produced from the information in the provided record.
• A quantified market analysis and forecast for the same combination cannot be produced from the information in the provided record.
• Any computed projection or ranking would lack the required verifiable inputs for accuracy and auditability.

---

FAQs

1. Is there an active global clinical development program for ibuprofen plus pseudoephedrine hydrochloride?
   Not determinable from the provided record.

2. Is the combination marketed mainly as an OTC product or via prescriptions?
   Not determinable from the provided record.

3. What endpoints matter most for ibuprofen plus pseudoephedrine trials?
   Not determinable from the provided record.

4. What regulatory constraints affect pseudoephedrine-containing combination products by region?
   Not determinable from the provided record.

5. How should investors model demand for the combination versus mono-therapies?
   Not determinable from the provided record.

---

References

No sources were provided in the prompt record, so no citations can be listed.